Skip to content
Signal Bureau What’s happening · what the record shows

Amgen

One of the largest biotechs — bone, cardiovascular, and cancer biologics.

Coverage of Amgen is holding steady : 3 signals on the latest tracked day, up 50% from its three-week baseline of 2, across 2 domains (down from 3 a week ago). That makes it the #134 most-covered of the 274 concerns we track.

What’s changed

What the reporting says

Across 26 tracked stories from 12 outlets, reporting on Amgen most often describes IPOs or listings (3), regulatory approvals (3), legal rulings (2), price levels (1), acquisition (1), launches or releases (1).

It shows up alongside FDA (10).

Two steps out: AI (through FDA, 10 shared stories on the weaker link); China (through FDA, 10 shared stories on the weaker link); CMS (through FDA, 10 shared stories on the weaker link); Colorectal Cancer (through FDA, 10 shared stories on the weaker link).

Tracked since Jun 21, with coverage on 16 separate days — concentrated in Biotech Pharma and Pharma Pipeline.

Ask the engine about Amgen + Track Amgen for a daily read
Counts computed from our committed signal record (Jul 22 – Aug 5, 4 tracked days). Informational only — not financial, legal, or investment advice. Prediction-market prices are shown as a signal of what the crowd believes. Terms · Privacy · page rendered Aug 8, 8:50 PM PT